Omalizumab effective for patients with both asthma and allergic rhinitis.(Clinical Rounds)

Publication: Skin & Allergy News

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 International Medical News Group

SAN FRANCISCO -- When added to standard therapies, omalizumab, an anti-IgE antibody, appears effective in treating patients who have both moderate to severe allergic asthma and persistent allergic rhinitis, according to a poster presented by Dr. R. Dahl at the annual meeting of the American Academy of Allergy, Asthma,...

Read the full article for free courtesy of your local library.